Crystal morphology engineering of pharmaceutical solids: Tabletting performance enhancement

AAPS PharmSciTech

Volumn 10, Issue 1, 2009, Pages 113-119

  Mirza, Sabiruddin ^a   Miroshnyk, Inna ^a   Heinämäki, Jyrki ^a   Antikainen, Osmo ^a   Rantanen, Jukka ^b   Vuorela, Pia ^c   Vuorela, Heikki ^a   Yliruusi, Jouko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ÅBO AKADEMI UNIVERSITY   (Finland)

Author keywords

Crystal engineering; Crystal habit; Erythromycin A dihydrate; Hydroxypropyl cellulose; Tabletting properties

Indexed keywords

ERYTHROMYCIN; HYDROXYPROPYLCELLULOSE; MACROLIDE; ANTIINFECTIVE AGENT; CELLULOSE; DRUG DERIVATIVE; EXCIPIENT;

ARTICLE; CHEMICAL ENGINEERING; CHEMICAL INTERACTION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DETERMINATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TRANSFORMATION; INTERMETHOD COMPARISON; MOLECULAR MODEL; PHYSICAL CHEMISTRY; STRUCTURE ANALYSIS; TABLET COMPRESSION; TABLET MANUFACTURE; TABLET SURFACE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; COMPUTER SIMULATION; CONFORMATION; CRYSTALLIZATION; METHODOLOGY; PHARMACEUTICS; SURFACE PROPERTY; TABLET;

ANTI-BACTERIAL AGENTS; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; CRYSTALLIZATION; ERYTHROMYCIN; EXCIPIENTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; SURFACE PROPERTIES; TABLETS; TECHNOLOGY, PHARMACEUTICAL;

EID: 67549121775     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9187-4     Document Type: Article

References (37)

1. C. R. Gardner, C. T. Walsh, and O. Almarsson. Drugs as materials: valuing physical form in drug discovery. Nat. Rev. Drug Discov. 3:926-934 (2004).
2. P. York. Crystal engineering and particle design for the powder compaction process. Drug Dev. Ind. Pharm. 18:677-721 (1992).
3. N. Blagden, M. de Matas, P. T. Gavan, and P. York. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Deliv. Rev. 59:617-630 (2007).
4. P. York. Solid-state properties of powders in the formulation and processing of solid dosage forms. Int. J. Pharm. 14:1-28 (1983).
5. S. Datta, and D. J. Grant. Crystal structures of drugs: Advances in determination prediction and engineering. Nat. Rev. Drug Discov. 3:42-57 (2004).
6. R. Bandyopadhyay, and D. J. Grant. Influence of crystal habit on the surface free energy and interparticulate bonding of L-lysine monohydrochloride dihydrate. Pharm. Dev. Technol. 5:27-37 (2000).
7. J. T. Carstensen. Advanced pharmaceutical solids, Marcel Dekker, New York, 2001.
8. C. Sun, and D. J. Grant. Influence of crystal shape on the tableting performance of l -lysine monohydrochloride dihydrate. J. Pharm. Sci. 90:569-579 (2001).
9. J. K. Haleblian. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J. Pharm. Sci. 64:1269-1288 (1975).
10. R. J. Davey, J. W. Mullin, and M. J. L. Whiting. Habit modification of succinic acid crystals grown from different solvents. J. Cryst Growth. 58:304-312 (1982).
11. P. V. Marshall, and P. York. Crystallization solvent induced solid-state and particulate modifications of nitrofurantoin. Int. J. Pharm. 55:257-263 (1989).
12. H. A. Garekani, F. Sadeghi, A. Badiee, S. A. Mostafa, and AR Rajabi-Siahboomi. Crystal habit modifications of ibuprofen and their physicomechanical characteristics. Drug Dev. Ind. Pharm. 27:803-809 (2001).
13. S. L. Raghavan, A. Trividic, A. F. Davis, and J. Hadgraft. Int. J. Pharm. 212:213-221 (2001).
14. N. Rodríguez-Hornedo, and D. Murphy. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph. J. Pharm. Sci. 93:449-460 (2004).
15. A. Kuldipkumar, Y. T. F. Tan, M. Goldstein, Y. Nagasaki, G. G. Z. Zhang, and G. S. Kwon. Amphiphilic diblock copolymer as crystal habit modifier. Cryst Growth Des. 5:1781-1785 (2005).
16. S. Mirza, I. Miroshnyk, J. Heinämäki, L. Christiansen, M. Karjalainen, and J. Yliruusi. Influence of solvents on the variety of crystalline forms of erythromycin. AAPS PharmSci. 52:12 (2003).
17. O. Antikainen, and J. Yliruusi. Determining the compression behavior of pharmaceutical powders from the force-distance compression profile. Int. J. Pharm. 252:253-261 (2003).
18. G. A. Stephenson, J. G. Stowell, P. H. Toma, R. R. Pfeiffer, and S. R. Byrn. Solid-state investigations of erythromycin A dihydrate: Structure NMR spectroscopy and hygroscopicity. J. Pharm. Sci. 86:1239-1244 (1997).
19. G. Friedel. Studies on the law of Bravais. Bull. Soc. Franc. Min. 30:326-455 (1907).
20. J. D. H. Donnay, and D. Harker. A new law of crystal morphology extending the law of Bravais. Am. Mineral. 22:446-467 (1937).
21. M. Lang, A. L. Gzesiak, and A. J. Matzger. The use of polymer heteronuclei for crystalline polymorph selection. J. Am. Chem. Soc. 124:14834-14835 (2002).
22. T. Mukuta, A. Y. Lee, T. Kawakami, and A. S. Myerson. Influence of impurities on the solution-mediated phase transformation of an active pharmaceutical ingredient. Cryst. Growth Des. 5:1429-1436 (2005).
23. L.-F. Huang, and W.-Q. Tong. Impact of solid state properties on developability assessment of drug candidates. Adv. Drug Deliv. Rev. 56:321-334 (2004).
24. S. Mirza, J. Heinämäki, I. Miroshnyk, J. Rantanen, L. Christiansen, M. Karjalainen, and J. Yliruusi. Understanding processing-induced phase transformations in erythromycin-PEG 6000 solid dispersions. J. Pharm. Sci. 95:1723-1732 (2006).
25. G. A. Stephenson, E. G. Groleau, R. L. Kleemann, W. Xu, and D. R. Rigsbee. Formation of isomorphic desolvates: Creating a molecular vacuum. J. Pharm. Sci. 87:536-542 (1998).
26. I. Miroshnyk, L. Khriachtchev, S. Mirza, J. Rantanen, J. Heinämäki, and J. Yliruusi. Cryst Growth Des. 6:369-374 (2006).
27. I. Miroshnyk, S. Mirza, P. M. Zorkii, A. E. Obodovskaya, J. Heinämäki, and J. Yliruusi. Interpretation of pharmacokinetic properties of erythromycin and its derivatives on the basis of calculation of intermolecular interaction energy in crystals. AAPSPharmSci. 3(S1) (2001).
28. F. Tian, N. Sandler, K. C. Gordon, C. M. McGoverin, A. Reay, C. J. Strachan, D. J. Saville, and T. Rades. Visualizing the conversion of carbamazepine in aqueous suspension with and without the presence of excipients: A single crystal study using SEM and Raman microscopy. Eur. J. Pharm. Biopharm. 64:326-335 (2006).
29. J. Y. Y. Heng, A. Bismarck, and D. R. Williams. Anisotropic surface chemistry of crystalline pharmaceutical solids. AAPS PharmSciTech. 7(4) (2006).
30. I. Katzhendler, R. Azoury, and M. Friedman. Crystalline properties of carbamazepine in sustained release hydrophilic matrix tablet based on hydroxypropyl methylcellulose. J. Control Release. 54:69-85 (1998).
31. H. Wen, K. R. Morris, and K. J. Park. Hydrogen bonding interactions between adsorbed polymer molecules and crystal surface of acetaminophen. J. Colloid Interface Sci. 290:325-335 (2005).
32. R. J. Roberts, R. C. Rowe, and P. York. The relationship between the fracture properties, tensile strength, and critical stress intensity factor of organic solids and their molecular structure. Int. J. Pharm. 125:157-162 (1995).
33. Y. Feng, and D. J. Grant. Influence of crystal structure on the compaction properties of n -alkyl 4-hydroxybenzoate esters (parabens). Pharm. Res. 23:1608-1616 (2006).
34. J. W. Shell. X-ray and crystallographic applications in pharmaceutical research. III. Crystal habit quantitation. J. Pharm. Sci. 52:100-101 (1963).
35. R. Bandyopadhyay, and D. J. Grant. Plasticity and slip system of plate-shaped crystals of l -lysine monohydrochloride dihydrate. Pharm. Res. 19:491-496 (2002).
36. A. P. Plumb, R. C. Rowe, P. York, and M. Brown. Optimisation of the predictive ability of artificial neural network (ANN) models: A comparison of three ANN programs and four classes of training algorithm. Eur. J. Pharm. Sci. 25:395-405 (2005).
37. Q. Shao, R. C. Rowe, and P. York. Comparison of neurofuzzy logic and decision trees in discovering knowledge from experimental data of an immediate release tablet formulation. Eur. J. Pharm. Sci. 31:129-136 (2007).